Quizartinib

Drug Profile

Quizartinib

Alternative Names: AC-010220; AC-220; ASP-2689

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • No development reported Acute lymphoblastic leukaemia; Solid tumours

Most Recent Events

  • 03 Dec 2016 Leukaemia and Lymphoma Research Institute and National Cancer Research Institute terminates the AML-LI-1 trial in Acute myeloid leukaemia (Combination therapy, First line therapy) in United Kingdom and Denmark
  • 03 Dec 2016 Interim efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndrome and Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top